TheProductLawyers.com reports on the U.S. Food and Drug Administration's (FDA) 2011 approval of Xarelto and the legal controversies centered on the drug that have arisen since then. The drug was approved to treat patients recovering from hip and knee replacement surgeries, as well as to prevent strokes and blood clots, with a subsequent treatment for atrial fibrillation coming later. Since the FDA's approved the drug, it has been the focus of over 3,400 lawsuits as well as the recipient of two black box warnings by the FDA that generally portends a product's removal from the consumer market.
Up until October 2015, all of the lawsuits filed against the makers of Xarelto, Bayer AG and a Johnson and Johnson subdivision, Janssen Pharmaceuticals, have been focused on plaintiff allegations that the drug caused serious uncontrollable and sometimes fatal internal bleeding. These cases have been consolidated into two primary groups. The first is a mass tort program in Philadelphia, PA encompassing over 550 cases. The second is a multidistrict litigation (MDL 2592) encompassing in excess of 2,800 cases in an Eastern Louisiana court.
However, in October of 2015, a new lawsuit was filed that veered from these standard accusations and focused instead on the ineffectiveness of the daily dosage requirement of Xarelto that did not take into account a patient's size or weight. With the exception of Xarelto, the other blood thinning drugs on the market require a patient to take it twice daily to keep it in the patient's system for a 24-hour period. Xarelto's dosage is a once daily regimen.
The plaintiff in this trailblazing case claims that the once daily requirement is ineffective. He was given Xarelto to prevent strokes due to his atrial fibrillation. However, after only taking the drug for four days, he suffered a stroke. The plaintiff is claiming that not only did the drug not prevent his stroke as he was told it would, he firmly believes that it may have also caused it to happen.
The attorneys of Banville Law, the firm behind TheProductLawyers.com, are offering complimentary consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. For more information about this release or the Xarelto litigation call 888-997-3792.
TheProductLawyers.com is a resource website sponsored by Banville Law to provide information on pending lawsuits against defective products, drugs and medical devices.
165 West End Ave #1h,
New York, NY 10023
November 30, 2016 – Research Indicates New Form Of Treating Ovarian Cancer As Talcum Powder Lawsuit Numbers Climb
November 30, 2016 – Parties in Talcum Powder Lawsuit In Missouri Exchange Briefings
November 30, 2016 – J&J Requests Disclosure Of Third Party Litigation Financing In Talcum Powder Lawsuit
November 30, 2016 – Delaware Sees 10 New Talcum Powder Lawsuit Filings
November 29, 2016 – Philadelphia Talcum Powder Lawsuit Filed Against Johnson & Johnson To Proceed
November 29, 2016 – Pennsboro Woman Files Talcum Powder Lawsuit On Behalf Of Her Deceased Mother
November 29, 2016 – Bioimaging Helps Early Detection Of Ovarian Cancer As Talcum Powder Lawsuit Filings Continue
November 28, 2016 – FDA Follow-Up: How Officials Have Responded To The Influx Of Talcum Powder Lawsuit Filings
November 28, 2016 – Talc Uses: A Look At The Product At The Center Of Talcum Powder Lawsuit Filings
November 28, 2016 – More Women Encouraged To File A Talcum Powder Lawsuit After Verdicts